Dung Le, MD
SKCCC Johns Hopkins Medical Institution · Johns Hopkins Medical Institution · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Dung Le, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 12:17 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT04753879 · Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer.Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · completed · Metastatic Pancreatic Cancer · principal investigator
- Ph2NCT04177810 · Plerixafor and Cemiplimab in Metastatic Pancreatic CancerSidney Kimmel Comprehensive Cancer Center at Johns Hopkins · completed · Metastatic Pancreatic Cancer · principal investigator
- Ph2NCT04098068 · Study of MK-3475 (Pembrolizumab) in Patients With Microsatellite Unstable (MSI) Tumors (Cohort D)Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · completed · High Tumor Mutation Burden, High TMB (Tumor Mutation Burden), MSS (Microsatellite Stable) · principal investigator
- Ph2NCT03642067 · Study of Nivolumab and Relatlimab in Patients With Microsatellite Stable (MSS) Advanced Colorectal CancerSidney Kimmel Comprehensive Cancer Center at Johns Hopkins · completed · Microsatellite Stable (MSS) Colorectal Adenocarcinomas, Colorectal Adenocarcinoma · principal investigator
- Ph2NCT03607890 · Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 InhibitorSidney Kimmel Comprehensive Cancer Center at Johns Hopkins · active not recruiting · Refractory MSI - H Solid Tumors Prior of PD-(L) 1 Therapy, MSI-H Tumors · principal investigator
- Ph1/Ph2NCT03535727 · A Study of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan in Metastatic Pancreatic CancerSidney Kimmel Comprehensive Cancer Center at Johns Hopkins · completed · Adenocarcinoma, Pancreatic Neoplasms, Neoplasm, Glandular · principal investigator
- Ph2NCT03190265 · Study of CRS-207, Nivolumab, and Ipilimumab With or Without GVAX Pancreas Vaccine (With Cy) in Patients With Pancreatic CancerSidney Kimmel Comprehensive Cancer Center at Johns Hopkins · completed · Pancreatic Cancer · principal investigator
- Ph1/Ph2NCT02324543 · Study of Gemcitabine/Taxotere/Xeloda (GTX) in Combination With Cisplatin and Irinotecan in Subjects With Metastatic Pancreatic CancerSidney Kimmel Comprehensive Cancer Center at Johns Hopkins · completed · Metastatic Pancreatic Adenocarcinoma · principal investigator
- Ph2NCT02243371 · GVAX Pancreas Vaccine (With CY) and CRS-207 With or Without NivolumabSidney Kimmel Comprehensive Cancer Center at Johns Hopkins · completed · Previously Treated Metastatic Adenocarcinoma of the Pancreas · principal investigator
- Ph1NCT02048384 · A Study of Metformin With or Without Rapamycin as Maintenance Therapy After Induction Chemotherapy in Subjects With Pancreatic CancerSidney Kimmel Comprehensive Cancer Center at Johns Hopkins · completed · Metastatic Pancreatic Adenocarcinoma · study chair
- Ph2NCT01876511 · Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors (Cohorts A, B and C)Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · completed · MSI Positive Colorectal Cancer, MSI Negative Colorectal Cancer, MSI Positive Non-Colorectal Cancers · principal investigator
- Ph2NCT01459614 · Gemcitabine/Taxotere/Xeloda (GTX) With Cisplatin in Subjects With Metastatic Pancreatic CancerSidney Kimmel Comprehensive Cancer Center at Johns Hopkins · completed · Pancreatic Cancer · principal investigator
- Ph1NCT00836407 · Ipilimumab +/- Vaccine Therapy in Treating Patients With Locally Advanced, Unresectable or Metastatic Pancreatic CancerSidney Kimmel Comprehensive Cancer Center at Johns Hopkins · completed · Pancreatic Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 12:17 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Integration of neo-antigen vaccines and immune checkpoint therapyP01CA247886 · NCI · JOHNS HOPKINS UNIVERSITY · PI ELIZABETH M. JAFFEE · fiscal years 2021 to 2025Named on NCT04177810, NCT03190265
- Administrative CoreP50CA062924 · NCI · JOHNS HOPKINS UNIVERSITY · PI Alison P Klein · fiscal years 1993 to 2022Named on NCT03607890
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in colorectal cancer.